Page 9 - Alkermes News Today

Headlands Technologies LLC acquired a new position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,881 shares of the company’s stock, valued at approximately $53,000. Other large investors also recently modified their […]

/PRNewswire/ -- The "Modified Release Neurology Therapeutics" report has been added to ResearchAndMarkets.coms offering. Large pharmaceutical and...

Nicollet Investment Management Inc. raised its stake in Alkermes plc (NASDAQ:ALKS – Free Report) by 2.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,095 shares of the company’s stock after buying an additional 624 shares during the period. Nicollet Investment Management Inc.’s […]

Nicollet Investment Management Inc. lifted its position in Alkermes plc (NASDAQ:ALKS – Free Report) by 2.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 27,095 shares of the company’s stock after purchasing an additional 624 shares during the quarter. Nicollet Investment […]

BioPharma

DUBLIN, Feb. 8, 2024 /PRNewswire/ -- Alkermes plc will host a conference call and webcast presentation at 8:00 a.m. ET on Thursday, Feb. 15, 2024 to discuss the companys fourth quarter and...

Our January 2024 psychiatry month in review includes studies finding associations with depression, anxiety, and anorexia nervosa, as well as a phase 3 study looking into long-term safety of olanzapine, samidorphan.

These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns

Here are some updates from the world of psychiatry throughout the month of January.